DK3439661T3 - Fremgangsmåder til behandling af øjenlidelser - Google Patents

Fremgangsmåder til behandling af øjenlidelser Download PDF

Info

Publication number: DK3439661T3
Authority: DK; Denmark
Prior art keywords: procedures; treatment; eye disorders; disorders; eye
Prior art date: 2016-04-07

Application number

DK17718304.3T

Other languages

English (en)

Inventor

Douglas Michael Ackermann

Kenneth J Mandell

James Loudin

Original Assignee

Oyster Point Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-04-07

Filing date

2017-04-06

Publication date

2021-10-18

2017-04-06 Application filed by Oyster Point Pharma Inc filed Critical Oyster Point Pharma Inc

2021-10-18 Application granted granted Critical

2021-10-18 Publication of DK3439661T3 publication Critical patent/DK3439661T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

DK17718304.3T 2016-04-07 2017-04-06 Fremgangsmåder til behandling af øjenlidelser DK3439661T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662319648P	2016-04-07	2016-04-07
PCT/US2017/026385 WO2017177024A1 (en)	2016-04-07	2017-04-06	Methods of treating ocular conditions

Publications (1)

Publication Number	Publication Date
DK3439661T3 true DK3439661T3 (da)	2021-10-18

Family

ID=58549326

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK17718304.3T DK3439661T3 (da)	2016-04-07	2017-04-06	Fremgangsmåder til behandling af øjenlidelser

Country Status (20)

Country	Link
US (3)	US10709707B2 (da)
EP (2)	EP3439661B1 (da)
JP (3)	JP7090551B2 (da)
KR (2)	KR102512777B1 (da)
CN (3)	CN109310692B (da)
AU (1)	AU2017248276B2 (da)
CA (1)	CA3020170A1 (da)
DK (1)	DK3439661T3 (da)
EA (1)	EA201892265A1 (da)
ES (1)	ES2893126T3 (da)
IL (3)	IL299204A (da)
MX (2)	MX385698B (da)
MY (1)	MY199237A (da)
NZ (1)	NZ746468A (da)
PH (1)	PH12018502154A1 (da)
PT (1)	PT3439661T (da)
SG (1)	SG11201808650QA (da)
TW (2)	TWI790997B (da)
WO (1)	WO2017177024A1 (da)
ZA (1)	ZA201807438B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9145396B2 (en)	2008-12-01	2015-09-29	Targacept, Inc.	Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
PT3848028T (pt)	2014-10-20	2024-09-20	Oyster Point Pharma Inc	Métodos de tratamento de estados oculares
DK3439661T3 (da)	2016-04-07	2021-10-18	Oyster Point Pharma Inc	Fremgangsmåder til behandling af øjenlidelser
EP3820443A1 (en)	2018-07-10	2021-05-19	Oyster Point Pharma, Inc.	Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions
WO2020014217A1 (en)	2018-07-10	2020-01-16	Oyster Point Pharma, Inc.	Methods of treating ocular conditions
ES3039903T3 (en) *	2020-04-28	2025-10-27	Oyster Point Pharma Inc	Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
EP4333855A4 (en) *	2021-05-07	2025-07-09	Oyster Point Pharma Inc	CO-THERAPY WITH A VECTOR AND A NICOTINIC AGONIST

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6277855B1 (en) *	2000-04-21	2001-08-21	Inspire Pharmaceuticals, Inc.	Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US20030008892A1 (en)	2001-07-09	2003-01-09	Pfizer Inc.	Pharmaceutical composition and method of modulating cholinergic function in a mammal
KR20040066140A (ko)	2001-11-29	2004-07-23	화이자 프로덕츠 인크.	5,8,14-트리아자테트라시클로[10.3.1.0(2,11).0(4,9)]헥사데카-2(11),3,5,7,9-펜타엔의 숙신산염 및 그의 제약 조성물
WO2004039366A1 (en) *	2002-11-01	2004-05-13	Pharmacia & Upjohn Company Llc	Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7098331B2 (en)	2003-03-05	2006-08-29	Targacept, Inc.	Arylvinylazacycloalkane compounds and methods of preparation and use thereof
US20060270592A1 (en)	2004-03-19	2006-11-30	Ophthalmic Research Associates, Inc.	Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
CA2583101A1 (en)	2004-10-15	2006-04-20	Pfizer Products Inc.	Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline
WO2006100075A2 (en)	2005-03-22	2006-09-28	Niconovum Ab	Use of an artificial sweetener to enhance absorption of nicotine
US20110086086A1 (en)	2005-07-26	2011-04-14	Pfizer Inc	Transdermal system for varenicline
TWI454262B (zh)	2006-11-02	2014-10-01	Targacept Inc	菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
CA2676670C (en)	2007-02-02	2012-03-13	Pfizer Products Inc.	Tricyclic compounds, compositions, and methods
WO2008157365A2 (en) *	2007-06-15	2008-12-24	Targacept, Inc.	Vinylazacycloalkanes for treating neuropathic pain
US20090093446A1 (en)	2007-10-05	2009-04-09	Winston Laboratories, Inc.	Method for alleviating keratoconjunctivitis sicca
CL2008003507A1 (es)	2007-11-26	2009-11-27	Neuroderm Ltd	Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
CA2716863A1 (en)	2008-03-05	2009-09-11	Targacept, Inc.	Sub-type selective amides of diazabicycloalkanes
WO2010028011A1 (en)	2008-09-05	2010-03-11	Targacept, Inc.	Amides of diazabicyclononanes and uses thereof
EP2344496A1 (en)	2008-09-05	2011-07-20	Targacept Inc.	Amides of diazabicyclooctanes and uses thereof
JP2012505834A (ja) *	2008-10-14	2012-03-08	サイコジェニックス・インコーポレーテッド	ニコチン性アセチルコリン受容体リガンドおよびその使用
ES2820857T3 (es)	2008-12-01	2021-04-22	Oyster Point Pharma Inc	Síntesis y formas de sal novedosas de (R)-5-((E)-2-pirrolidin-3-ilvinil)pirimidina
US9145396B2 (en) *	2008-12-01	2015-09-29	Targacept, Inc.	Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
TW201024283A (en)	2008-12-01	2010-07-01	Targacept Inc	Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
CA2763551A1 (en) *	2009-06-17	2010-12-23	Targacept, Inc.	Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands
US20110274628A1 (en)	2010-05-07	2011-11-10	Borschke August J	Nicotine-containing pharmaceutical compositions
US8821457B2 (en)	2010-09-08	2014-09-02	Johnson & Johnson Vision Care, Inc.	Punctal plug containing drug formulation
CA3083244C (en)	2011-10-20	2023-01-03	Novartis Ag	Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
WO2013080196A1 (en)	2011-11-30	2013-06-06	D.E.S. Diagnostics Ltd.	Dry eye diagnostic
PT3848028T (pt) *	2014-10-20	2024-09-20	Oyster Point Pharma Inc	Métodos de tratamento de estados oculares
DK3439661T3 (da) *	2016-04-07	2021-10-18	Oyster Point Pharma Inc	Fremgangsmåder til behandling af øjenlidelser

2017
- 2017-04-06 DK DK17718304.3T patent/DK3439661T3/da active
- 2017-04-06 PT PT177183043T patent/PT3439661T/pt unknown
- 2017-04-06 EP EP17718304.3A patent/EP3439661B1/en active Active
- 2017-04-06 NZ NZ746468A patent/NZ746468A/en unknown
- 2017-04-06 MX MX2018012230A patent/MX385698B/es unknown
- 2017-04-06 KR KR1020237000103A patent/KR102512777B1/ko active Active
- 2017-04-06 SG SG11201808650QA patent/SG11201808650QA/en unknown
- 2017-04-06 JP JP2018553080A patent/JP7090551B2/ja active Active
- 2017-04-06 MY MYPI2018001700A patent/MY199237A/en unknown
- 2017-04-06 EA EA201892265A patent/EA201892265A1/ru unknown
- 2017-04-06 AU AU2017248276A patent/AU2017248276B2/en active Active
- 2017-04-06 EP EP21189296.3A patent/EP3970724A1/en active Pending
- 2017-04-06 TW TW106111559A patent/TWI790997B/zh active
- 2017-04-06 CN CN201780034734.3A patent/CN109310692B/zh active Active
- 2017-04-06 KR KR1020187032218A patent/KR102485299B1/ko active Active
- 2017-04-06 IL IL299204A patent/IL299204A/en unknown
- 2017-04-06 US US16/091,830 patent/US10709707B2/en active Active
- 2017-04-06 CA CA3020170A patent/CA3020170A1/en active Pending
- 2017-04-06 CN CN202210034408.5A patent/CN114533737B/zh active Active
- 2017-04-06 CN CN202210040168.XA patent/CN114432313A/zh active Pending
- 2017-04-06 WO PCT/US2017/026385 patent/WO2017177024A1/en not_active Ceased
- 2017-04-06 ES ES17718304T patent/ES2893126T3/es active Active
- 2017-04-06 TW TW112102845A patent/TWI876258B/zh active
2018
- 2018-10-03 IL IL262102A patent/IL262102B/en unknown
- 2018-10-05 MX MX2021010399A patent/MX2021010399A/es unknown
- 2018-10-05 PH PH12018502154A patent/PH12018502154A1/en unknown
- 2018-11-06 ZA ZA2018/07438A patent/ZA201807438B/en unknown
2020
- 2020-04-17 US US16/852,225 patent/US20200345734A1/en not_active Abandoned
2022
- 2022-01-24 IL IL290069A patent/IL290069B2/en unknown
- 2022-06-14 JP JP2022095460A patent/JP2022120125A/ja active Pending
2024
- 2024-05-29 JP JP2024086805A patent/JP2024103594A/ja active Pending
- 2024-09-05 US US18/825,758 patent/US20250000861A1/en active Pending

Also Published As

Publication number	Publication date
MY199237A (en)	2023-10-22
EP3439661A1 (en)	2019-02-13
US20200345734A1 (en)	2020-11-05
KR102512777B1 (ko)	2023-03-23
EA201892265A1 (ru)	2019-04-30
US20250000861A1 (en)	2025-01-02
NZ746468A (en)	2023-06-30
TW201737917A (zh)	2017-11-01
IL299204A (en)	2023-02-01
CN114533737B (zh)	2024-05-31
JP2022120125A (ja)	2022-08-17
TWI790997B (zh)	2023-02-01
SG11201808650QA (en)	2018-10-30
EP3970724A1 (en)	2022-03-23
KR20190005859A (ko)	2019-01-16
AU2017248276B2 (en)	2023-07-13
MX2018012230A (es)	2019-03-28
CN109310692B (zh)	2022-01-25
KR102485299B1 (ko)	2023-01-06
MX385698B (es)	2025-03-18
CN114432313A (zh)	2022-05-06
ZA201807438B (en)	2024-09-25
PT3439661T (pt)	2021-09-30
KR20230010813A (ko)	2023-01-19
WO2017177024A8 (en)	2018-11-08
IL290069A (en)	2022-03-01
IL290069B2 (en)	2023-05-01
IL262102A (en)	2018-11-29
WO2017177024A1 (en)	2017-10-12
US20190201397A1 (en)	2019-07-04
EP3439661B1 (en)	2021-08-04
NZ785093A (en)	2024-07-05
ES2893126T8 (es)	2022-05-23
JP2024103594A (ja)	2024-08-01
JP7090551B2 (ja)	2022-06-24
TW202320785A (zh)	2023-06-01
TWI876258B (zh)	2025-03-11
PH12018502154A1 (en)	2019-07-08
US10709707B2 (en)	2020-07-14
CA3020170A1 (en)	2017-10-12
AU2017248276A1 (en)	2018-11-22
CN109310692A (zh)	2019-02-05
CN114533737A (zh)	2022-05-27
BR112018070497A2 (pt)	2019-01-29
MX2021010399A (es)	2022-01-18
IL290069B1 (en)	2023-01-01
ES2893126T3 (es)	2022-02-08
IL262102B (en)	2022-03-01
JP2019513759A (ja)	2019-05-30

Publication	Publication Date	Title
IL285151A (en)	2021-08-31	Methods of treating fgf21-associated disorders
DK3570844T3 (da)	2023-11-13	Azolopyrimidin til behandlingen af kræftrelaterede lidelser
DK3261640T3 (da)	2022-07-11	5ht-agonister til behandling af epilepsilidelser
DK3386511T3 (da)	2021-07-05	Fremgangsmåder til behandling af huntingtons sygdom
DK3185876T3 (da)	2022-10-31	Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
DK3240612T3 (da)	2021-01-18	Fremgangsmåder til behandling af nethindesygdomme
DK3399962T3 (da)	2020-09-07	Oftalmisk sammensætning til behandling af tør øjensygdom
IL247452A0 (en)	2016-11-30	Compounds for treatment of complement mediated disorders
DK3288577T3 (da)	2022-01-10	Adiponectin-peptidomimetika til behandling af øjenlidelser
DK3265085T3 (da)	2022-10-03	Fremgangsmåder til behandling af forstyrrelser med abnorme ufrivillige bevægelser
DK3362066T3 (da)	2021-11-22	Kombinationsterapi til behandling af maligniteter
DK3433266T3 (da)	2025-08-25	Fremgangsmåder til behandling af mitokondrieforstyrrelser
HUE055263T2 (hu)	2021-11-29	11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
DK3390390T3 (da)	2021-12-06	Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
IL262852A (en)	2018-12-31	Treatment of complement-mediated disorders
DK3148529T3 (da)	2021-12-13	Forbindelser til behandling af hjernecancer
IL255185A0 (en)	2017-12-31	1-heteroaryl-indoline-4-carboxamides as modulators of gpr52 useful for the treatment or prevention of disorders related thereto
IL267229A (en)	2019-08-29	Methods of treating ocular disorders
DK3439661T3 (da)	2021-10-18	Fremgangsmåder til behandling af øjenlidelser
DK3419622T3 (da)	2024-06-03	Behandling af neurodegenerativ øjensygdom med pridopidin
DK3324824T3 (da)	2024-12-02	Fremgangsmåde til behandling af binokulare dysfunktioner
DK3192524T3 (da)	2022-02-14	Hgf præparat egnet til behandling af neurologiske lidelser
DK3210973T3 (da)	2021-02-08	Heteroarylforbindelser til behandling af oftalmiske sygdomme
DK3209295T3 (da)	2021-03-01	Fremgangsmåder til behandling af øjenlidelser
DK3261661T3 (da)	2024-01-15	Menotropin til behandling af infertilitet